Chimeric Therapeutics (ASX:CHM) Ending Cash Position : A$3.53 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Ending Cash Position?

Chimeric Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was A$3.53 Mil.

Chimeric Therapeutics's quarterly Ending Cash Position declined from Dec. 2022 (A$3.63 Mil) to Jun. 2023 (A$2.36 Mil) but then increased from Jun. 2023 (A$2.36 Mil) to Dec. 2023 (A$3.53 Mil).

Chimeric Therapeutics's annual Ending Cash Position declined from Jun. 2021 (A$22.41 Mil) to Jun. 2022 (A$18.38 Mil) and declined from Jun. 2022 (A$18.38 Mil) to Jun. 2023 (A$2.36 Mil).

Chimeric Therapeutics Ending Cash Position Historical Data

The historical data trend for Chimeric Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Ending Cash Position Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Ending Cash Position

22.41

18.38

2.36

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial			13.43	18.38	3.63	2.36	3.53

Chimeric Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Chimeric Therapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	18.382	+	-16.019
	=	2.36

Chimeric Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2.363	+	1.162
	=	3.53

Chimeric Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines